Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes
Type 2 diabetes is among the most prevalent chronic diseases worldwide and the prevention of associated cardiovascular complications is an important treatment goal. Sodium–glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2021-03-01
|
| Series: | Cardiac Failure Review |
| Online Access: | https://www.cfrjournal.com/articleindex/cfr.2020.19 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846122464409550848 |
|---|---|
| author | Chris Wai Hang Lo Yue Fei Bernard Man Yung Cheung |
| author_facet | Chris Wai Hang Lo Yue Fei Bernard Man Yung Cheung |
| author_sort | Chris Wai Hang Lo |
| collection | DOAJ |
| description | Type 2 diabetes is among the most prevalent chronic diseases worldwide and the prevention of associated cardiovascular complications is an important treatment goal. Sodium–glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors are second-line options after metformin, while cardiovascular outcome trials have been conducted to establish the cardiovascular safety of these antidiabetic drug classes. SGLT2 inhibitors have been shown to have the best overall mortality, renal and cardiovascular outcomes. Reduction in hospitalisation for heart failure is particularly consistent. GLP-1 receptor agonists have also showed some benefits, especially in stroke prevention. DPP-4 inhibitors showed neutral effects on cardiovascular outcomes, but may increase the incidence of heart failure. Favourable outcomes observed in trials of SGLT2 inhibitors mean that these should be the preferred second-line option. DPP-4 inhibitors are useful for patients with diabetes at low cardiovascular risk. |
| format | Article |
| id | doaj-art-5e0a92134d884fb9b6a7f7318868e0c3 |
| institution | Kabale University |
| issn | 2057-7540 2057-7559 |
| language | English |
| publishDate | 2021-03-01 |
| publisher | Radcliffe Medical Media |
| record_format | Article |
| series | Cardiac Failure Review |
| spelling | doaj-art-5e0a92134d884fb9b6a7f7318868e0c32024-12-14T16:02:34ZengRadcliffe Medical MediaCardiac Failure Review2057-75402057-75592021-03-01710.15420/cfr.2020.19Cardiovascular Outcomes in Trials of New Antidiabetic Drug ClassesChris Wai Hang Lo0Yue Fei1Bernard Man Yung Cheung2Division of Clinical Pharmacology and Therapeutics, Department of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, ChinaState Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Pokfulam, Hong Kong, ChinaDivision of Clinical Pharmacology and Therapeutics, Department of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China; State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Pokfulam, Hong Kong, China; Institute of Cardiovascular Science and Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China.Type 2 diabetes is among the most prevalent chronic diseases worldwide and the prevention of associated cardiovascular complications is an important treatment goal. Sodium–glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors are second-line options after metformin, while cardiovascular outcome trials have been conducted to establish the cardiovascular safety of these antidiabetic drug classes. SGLT2 inhibitors have been shown to have the best overall mortality, renal and cardiovascular outcomes. Reduction in hospitalisation for heart failure is particularly consistent. GLP-1 receptor agonists have also showed some benefits, especially in stroke prevention. DPP-4 inhibitors showed neutral effects on cardiovascular outcomes, but may increase the incidence of heart failure. Favourable outcomes observed in trials of SGLT2 inhibitors mean that these should be the preferred second-line option. DPP-4 inhibitors are useful for patients with diabetes at low cardiovascular risk.https://www.cfrjournal.com/articleindex/cfr.2020.19 |
| spellingShingle | Chris Wai Hang Lo Yue Fei Bernard Man Yung Cheung Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes Cardiac Failure Review |
| title | Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes |
| title_full | Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes |
| title_fullStr | Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes |
| title_full_unstemmed | Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes |
| title_short | Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes |
| title_sort | cardiovascular outcomes in trials of new antidiabetic drug classes |
| url | https://www.cfrjournal.com/articleindex/cfr.2020.19 |
| work_keys_str_mv | AT chriswaihanglo cardiovascularoutcomesintrialsofnewantidiabeticdrugclasses AT yuefei cardiovascularoutcomesintrialsofnewantidiabeticdrugclasses AT bernardmanyungcheung cardiovascularoutcomesintrialsofnewantidiabeticdrugclasses |